Table 2.
First author | Year | Comparison | Measure | Sensitivity | Specificity |
---|---|---|---|---|---|
Schrag20 | 2000 | 35 PSP-RS v 54 MSA | MB visual (MB atrophy) | 77 | 37 |
Adachi14 | 2004 | 5 PSP-RS v 23 PD 14 MSA | MB visual (morning glory sign) | 80 | 97 |
Righini25 | 2004 | 25 PSP-RS v 27 PD | MB visual (superior profile) | 68 | 88.8 |
Righini25 | 2004 | 25 PSP-RS v 27 PD | MB visual (MB atrophy) | 68 | 77.7 |
Price33 | 2004 | 12 PSP-RS v (12 PD, 12CN) | MB visual (MB atrophy) | 83 | 79 |
Massey13* | 2012 | 22 PSP v 13 MSA | MB visual (MB atrophy) | 86.4 | 66.7 |
Massey13* | 2012 | 22 PSP v 13 MSA | MB visual (Hummingbird) | 68.4 | 100 |
Oba16 | 2005 | 21 PSP-RS v (23 PD, 25 MSA-P, 31 HC) | MB area | 100 | 91.3 |
Cosottini15 | 2007 | 15 PSP-RS v (7 MSA-P, 14 CN) | MB area | 100 | 90.5 |
Zanigni17 | 2016 | 23 PSP-RS v 42 PD | MB area | 96 | 98 |
Moller32 | In Press | 106 PSP-RS v 204 PD | MB area | 84.0 | 83.8 |
Moller32 | In Press | 106 PSP-RS v 60 MSA-P | MB area | 78.3 | 81.7 |
Asato18 | 2000 | 8 PSP-RS v 9 MSA-P | MB diameter | 100 | 100 |
Asato18 | 2000 | 8 PSP-RS v 21 MSA-C | MB diameter | 100 | 91 |
Schrag20 | 2000 | 36 PSP-RS v 54 MSA | MB diameter | 23 | 96 |
Cosottini15 | 2007 | 17 PSP-RS v (7 MSA-P, 4 CN) | MB diameter | 60 | 95.2 |
Massey19* | 2013 | 12 PSP-RS v 7 MSA | MB diameter | 83 | 100 |
Kim22 | 2015 | 29 PSP-RS v 82 PD | MB diameter | 50 | 85.3 |
Owens21 | 2016 | 25 PSP-RS v (25 MSA, 25 PD) | MB diameter | 44 | 100 |
Paviour24 | 2006 | 18 PSP-RS v (9 MSA-P, 9 PD, 18 HC) | MB volume | 72.2 | 91.9 |
Paviour24 | 2006 | 18 PSP-RS v 9 MSA-P | MB volume | 83 | 33 |
Cosottini15 | 2007 | 18 PSP-RS v (7 MSA-P, 14 CN) | MB volume | 86.7 | 76.2 |
Oba16 | 2005 | 22 PSP-RS v (23 PD, 25 MSA-P, 31 HC) | MB-pons ratio | 100 | 100 |
Cosottini15 | 2007 | 16 PSP-RS v (7 MSA-P, 14 CN) | MB-pons ratio | 86.7 | 100 |
Quattrone38 | 2008 | 33 PSP-RS v 108 PD | MB-pons ratio | 90.9 | 93.5 |
Quattrone38 | 2008 | 33 PSP-RS v 19 MSA-P | MB-pons ratio | 97 | 94.7 |
Hussl41 | 2010 | 22 PSP-RS v 75 PD | MB-pons ratio | 63.6 | 94.7 |
Hussl41 | 2010 | 22 PSP-RS v 26 MSA-P | MB-pons ratio | 63.6 | 84.6 |
Morelli37 | 2011 | 42 PSP-RS v 170 PD | MB-pons ratio | 92.9 | 85.3 |
Longoni39 | 2011 | 10 PSP-RS v 25 PD | MB-pons ratio | 90 | 96 |
Massey19* | 2013 | 13 PSP-RS v 7 MSA | MB-pons ratio | 67 | 100 |
Kim22 | 2015 | 30 PSP-RS v 82 PD | MB-pons ratio | 46.2 | 89.7 |
Zanigni17 | 2016 | 24 PSP-RS v 42 PD | MB-pons ratio | 96 | 90 |
Owens23 | 2016 | 25 PSP-RS v (25 MSA, 25 PD) | MB-pons ratio | 68 | 100 |
Borroni45 | 2010 | 18 PSP-RS v (16 CBS, 28 FTD) | MB-pons ratio + CSF bio | 94.2 | 84 |
Sankhla40 | 2016 | 20 PSP-RS v 13 PD | MB-pons ratio | 100 | 92.86 |
Moller32 | In Press | 106 PSP-RS v 204 PD | MB-pons ratio | 77.4 | 80.4 |
Moller32 | In Press | 106 PSP-RS v 60 MSA-P | MB-pons ratio | 77.8 | 89.4 |
Quattrone38 | 2008 | 33 PSP-RS v 108 PD | MRPI | 100 | 100 |
Quattrone38 | 2008 | 33 PSP-RS v 19 MSA-P | MRPI | 100 | 100 |
Hussl41 | 2010 | 23 PSP-RS v 75 PD | MRPI | 81.8 | 76 |
Hussl41 | 2010 | 23 PSP-RS v 26 MSA-P | MRPI | 81.8 | 92.3 |
Morelli37 | 2011 | 42 PSP-RS v 170 PD | MRPI | 100 | 99.4 |
Longoni39 | 2011 | 10 PSP-RS v 25 PD | MRPI | 100 | 92 |
Kim22 | 2015 | 31 PSP-RS v 82 PD | MRPI | 92.3 | 39.7 |
Zanigni17 | 2016 | 25 PSP-RS v 42 PD | MRPI | 87 | 93 |
Nigro43 | 2016 | 88 PSP-RS v 234 PD | MRPI | 100 | 100 |
Nigro43 | 2016 | 88 PSP-RS v 234 PD | MRPI (automated) | 97.3 | 97.4 |
Sankhla40 | 2016 | 20 PSP-RS v 13 PD | MRPI | 100 | 100 |
Mostile44 | 2016 | 12 PSP-RS v 17 vascular parkinsonism | MRPI | 100 | 100 |
Moller32 | In Press | 106 PSP-RS v 204 PD | MRPI | 68.9 | 67.7 |
Moller32 | In Press | 106 PSP-RS v 60 MSA-P | MRPI | 79.0 | 64.1 |
PD = Parkinson's disease; MSA-P = parkinsonian variant of multiple system atrophy; MSA-C = cerebellar variant of multiple system atrophy; CBS = corticobasal syndrome; FTD = frontotemporal dementia; CN = cognitively normal controls; MB = midbrain; MRPI = MR parkinsonism index; CSF bio = cerebrospinal fluid biomarkers
Studies with autopsy-confirmed PSP